Naoaki Tamura Selected Research

Amniotic Fluid Embolism

12/2020	Consumptive Coagulopathy Involving Amniotic Fluid Embolism: The Importance of Earlier Assessments for Interventions in Critical Care.
1/2020	Acute inflammation in the uterine isthmus coincides with postpartum acute myometritis in the uterine body involving refractory postpartum hemorrhage of unknown etiology after cesarean delivery.
4/2017	Amniotic fluid embolism: Pathophysiology from the perspective of pathology.
7/2015	Therapeutic application of C1 esterase inhibitor concentrate for clinical amniotic fluid embolism: a case report.
6/2014	C1 esterase inhibitor activity in amniotic fluid embolism.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoaki Tamura Research Topics

Disease

5	Amniotic Fluid Embolism 12/2020 - 06/2014
3	Uterine Inertia 01/2020 - 01/2014
2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Thrombosis (Thrombus) 01/2022 - 01/2018
2	Anaphylaxis (Anaphylactic Shock) 01/2020 - 01/2014
2	Disseminated Intravascular Coagulation 06/2014 - 01/2014
2	Hemorrhage 06/2014 - 01/2014
2	Neoplasms (Cancer) 01/2013 - 12/2011
1	Chorioamnionitis 01/2020
1	Nonobstructive Azoospermia 09/2019
1	Edema (Dropsy) 08/2019
1	Hypoxia (Hypoxemia) 04/2017
1	Hypotension (Low Blood Pressure) 04/2017
1	Seizures (Absence Seizure) 04/2017
1	Shock 06/2014
1	Lacerations 01/2014
1	Body Weight (Weight, Body) 07/2013
1	Obesity 07/2013
1	Pulmonary Embolism 08/2005
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 08/2005
1	Thrombophilia 08/2005
1	Venous Thrombosis (Deep-Vein Thrombosis) 08/2005
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2004

Drug/Important Bio-Agent (IBA)

3	Dacarbazine (DIC)FDA LinkGeneric 04/2017 - 01/2014
2	FibrinIBA 01/2022 - 01/2018
2	Complement System Proteins (Complement)IBA 01/2020 - 06/2014
2	Kallikreins (Kallikrein)IBA 08/2019 - 06/2014
2	KininsIBA 08/2019 - 06/2014
2	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 07/2015 - 06/2014
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2022
1	Fibrinogen (Factor I)FDA Link 12/2020
1	Biomarkers (Surrogate Marker)IBA 12/2020
1	Hemoglobins (Hemoglobin)IBA 12/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	Luteinizing Hormone (Lutropin)FDA LinkGeneric 09/2019
1	Bradykinin Receptors (Bradykinin Receptor)IBA 08/2019
1	Complement C5a (Complement 5a)IBA 08/2019
1	AntithrombinsIBA 06/2014
1	Tryptases (Tryptase)IBA 01/2014
1	Complement Receptors (Complement Receptor)IBA 01/2014
1	AntigensIBA 07/2013
1	dimemorfan (AT 17)IBA 07/2013
1	Photosensitizing Agents (Photosensitizers)IBA 01/2013
1	HalogensIBA 01/2013
1	Singlet OxygenIBA 01/2013
1	Irinotecan (Camptosar)FDA LinkGeneric 12/2011
1	Pharmaceutical PreparationsIBA 12/2011
1	CarbohydratesIBA 12/2011
1	Peptides (Polypeptides)IBA 12/2011
1	Protein CIBA 08/2005
1	Thrombin FDA Link 08/2005
1	Metalloproteases (Metalloproteinases)IBA 01/2004
1	Tissue Inhibitor of Metalloproteinase-1IBA 01/2004
1	Polymyxin B (Aerosporin)FDA LinkGeneric 01/2004

Therapy/Procedure

1	Critical Care (Surgical Intensive Care) 12/2020
1	Hysterectomy 01/2020
1	Cesarean Section (Caesarean Section) 01/2020
1	Airway Management 06/2014
1	Therapeutics 06/2014
1	Caloric Restriction 07/2013
1	Photochemotherapy (Photodynamic Therapy) 01/2013